Skip to main content
. 2022 Jun 30;12(6):e059122. doi: 10.1136/bmjopen-2021-059122

Figure 3.

Figure 3

Heart failure (HF) medication prescription rates at discharge, according to comorbid respiratory disease status. ACEi, ACE Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antagonist.